| Document |
Document Title |
|
WO/2012/152739 |
The invention relates to compounds comprising at least one thioredoxin-like fold domain (CXXU) for use as medicament, particularly for use for the treatment and/or the prevention of degenerative disorders.
|
|
WO/2012/154354 |
The disclosure generally relates to the novel compounds of formula (I), including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using th...
|
|
WO/2012/154837 |
|
|
WO/2012/154956 |
Pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the...
|
|
WO/2012/154728 |
The present invention provides a compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof.
|
|
WO/2012/152983 |
Compounds of formula I, wherein A and R1-R7, are as defined in the claims, exhibit TRPA1 activity and useful as TRPA1 modulators.
|
|
WO/2012/154967 |
The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (Illa-IIId), (IVa-IVc), (Va-Vb), (Via- Vie), (VII), (Villa- VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, composition...
|
|
WO/2012/150829 |
The present invention relates to a noble triazolopyridine derivative or pharmaceutically acceptable salts thereof, a production method thereof, and a pharmaceutical composition including same. The noble triazolopyridine derivative of the...
|
|
WO/2012/150676 |
Provided are: a composition for inducing the expression of TNFR2, which contains a peptide having a high activity of inducing the expression of TNFR2 as an active ingredient; and a method for producing a cell that expresses TNFR2 in a se...
|
|
WO/2012/151343 |
Provided are compounds having formula I: ( l ) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as disclosed herein, or a pharmaceutically salt thereof. Pharmaceutical compositions comprising the compounds and methods of their use...
|
|
WO/2012/150495 |
Synthetic peptides and peptide copolymers for amelioration of autoimmune neurological syndrome, inflammatory and/or demyelinating conditions such as encephalomyletis are provided herein. The synthetic peptides and peptide copolymers as d...
|
|
WO/2012/150231 |
The present invention is concerned with novel selective dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein R1, R2, R3, n, and Y are as described herein, as well as pharmaceutically acceptable salts and esters thereof. ...
|
|
WO/2012/150829 |
The present invention relates to a noble triazolopyridine derivative or pharmaceutically acceptable salts thereof, a production method thereof, and a pharmaceutical composition including same. The noble triazolopyridine derivative of the...
|
|
WO/2012/149614 |
The present invention relates to the use of an antagonist of the non-selective cation channel TRPM3 as a medicine for the treatment of pain. The present invention further relates to a method for identification of novel compounds for the ...
|
|
WO/2012/150412 |
The invention relates to a combination of the 4-(3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy)benz
amide of formula (I), or of one of the addition salts thereof, with a pharmaceutically acceptable acid or base and an acetylcholin...
|
|
WO/2012/150543 |
The present invention is directed to the use of macrocyclic lactones, in particular avermectins, in the treatment of conditions whose formation, occurrence, development or growth is associated with aberrant Wnt signalling in particular t...
|
|
WO/2012/149024 |
Materials and methods related to using multimeric DNA aptamers to treat demyelinating diseases are provided herein.
|
|
WO/2012/149535 |
Angiotensin II (AT II) type 1 receptor antagonist in the therapeutic treatment of autism. Described herein are compositions and methods of administering to the patient a therapeutically effective amount of an angiotensin II type 1 recept...
|
|
WO/2012/149472 |
Provided herein are methods, compositions, and kits for diagnosing, prognosing, treating, and/or preventing a neurological condition, e.g., autism spectrum disorder (ASD). Methods for treating and/or preventing ASD can comprise administe...
|
|
WO/2012/149335 |
The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states ...
|
|
WO/2012/145893 |
A composition of entacapone comprising entacapone or pharmaceutically acceptable salts, PVPK30 and SDS is disclosed in the present invention, wherein the mass ratio of entacapone : PVPK30 : SDS is 1:0.05~0.6:0.06~0.1. The present inventi...
|
|
WO/2012/148887 |
Compositions and methods to improve cognitive performance and mood in an adult human subject's are presented herein. The method of the present invention involved the administration of a dietary supplement comprising plant polysaccharides...
|
|
WO/2012/149478 |
This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of Friedreich's ataxia or other neurodegenerative disease, and methods of employing the identified agents to prevent, reduc...
|
|
WO/2012/147764 |
Provided is a novel compound having NPY Y5 receptor antagonistic activity. It was discovered that a compound represented by (1) (where R1 is an optionally substituted alkyl and the like; p, q, and r are each independently 0 or 1; ring A ...
|
|
WO/2012/149406 |
This document provides methods and materials involved in assessing and treating humans with LQTS or with a potential mutation in a KCNQ1 nucleic acid that encodes a Kv7.1 potassium channel subunit. For example, methods and materials for ...
|
|
WO/2012/147765 |
Provided is a novel compound having an NPY Y5 receptor antagonist action. A compound represented by formula (I): (Chemical Formula 1) (in the formula, R1 is a substituted or unsubstituted alkyl or the like; p and q are each independently...
|
|
WO/2012/146651 |
This invention is directed to the use of a protein hydrolysate, and in particular an egg lysozyme hydrolysate to assist an animal, including a human in overcoming an addiction, or by breaking an unwanted habit.
|
|
WO/2012/149295 |
Pharmaceutical compositions comprising a compound of Formula I, e.g., an isolated form of anatabine or S-(-)-anatabine, or a pharmaceutically acceptable salt thereof, can be used to treat Autism Spectrum Disorders and seizure disorders.
|
|
WO/2012/149478 |
This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of Friedreich's ataxia or other neurodegenerative disease, and methods of employing the identified agents to prevent, reduc...
|
|
WO/2012/146724 |
The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of diseas...
|
|
WO/2012/148887 |
|
|
WO/2012/147597 |
The present invention addresses the problem of treating camptocormia related to the external abdominal oblique muscle. This problem can be solved by administering a local anesthetic to the external abdominal oblique muscle.
|
|
WO/2012/147986 |
Provided is a stable pharmaceutical composition containing ibuprofen and scopolamine butylbromide; the pharmaceutical composition containing components (A), (B), and (C) below. (A) ibuprofen; (B) scopolamine butylbromide; (C) at least on...
|
|
WO/2012/147051 |
Food, particularly a beverage for human consumption, the ingestion of which enhances cognitive processes such as intelligence, memory, creativity and mood, and/or produces energizing effects. Said food is composed of a composition diluta...
|
|
WO/2012/147805 |
The purpose of the present invention is to provide a novel therapeutic agent for Alzheimer's disease and use thereof. Provided is a therapeutic agent for Alzheimer's disease, which contains a CpG oligodeoxynucleotide structure having a b...
|
|
WO/2012/147099 |
The present invention relates to the pharmaceutical composition comprising two discrete portions of the mixtures of levodopa, carbidopa and entacapone or pharmaceutically acceptable salts or hydrates thereof and the process for preparing...
|
|
WO/2012/149472 |
|
|
WO/2012/148926 |
Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are m...
|
|
WO/2012/149024 |
Materials and methods related to using multimeric DNA aptamers to treat demyelinating diseases are provided herein.
|
|
WO/2012/146724 |
The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, -NH-, or a direct bond; Y is -NH- or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical co...
|
|
WO/2012/147916 |
A compound represented by general formula [I-W], or pharmaceutically acceptable salt thereof. (The symbols that appear in the formula are as described in the description.)
|
|
WO/2012/147051 |
Food, particularly a beverage for human consumption, the ingestion of which enhances cognitive processes such as intelligence, memory, creativity and mood, and/or produces energizing effects. Said food is composed of a composition diluta...
|
|
WO/2012/147763 |
Provided is a compound, for example a compound represented by formula (I), or a pharmaceutically acceptable salt of the same, which has amyloid β production inhibitory activity, has, in particular, BACE1 inhibitor activity, and can be u...
|
|
WO/2012/148926 |
Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are m...
|
|
WO/2012/146371 |
The present invention relates to novel solid forms of agomelatine (I), specifically novel pharmaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that h...
|
|
WO/2012/149295 |
Pharmaceutical compositions comprising a compound of Formula I, e.g., an isolated form of anatabine or S-(-)-anatabine, or a pharmaceutically acceptable salt thereof, can be used to treat Autism Spectrum Disorders and seizure disorders.
|
|
WO/2012/147762 |
Provided is a compound which has amyloid β production inhibitory activity, especially a BACE-1 inhibitory effect and is useful as a therapeutic agent for diseases induced by the production, secretion or deposition of amyloid β protein....
|
|
WO/2012/149335 |
The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states ...
|
|
WO/2012/146052 |
A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and ...
|
|
WO/2012/149406 |
This document provides methods and materials involved in assessing and treating humans with LQTS or with a potential mutation in a KCNQ1 nucleic acid that encodes a Kv7.1 potassium channel subunit. For example, methods and materials for ...
|
